

Class 42



COMPANY

PRODUCTS

R & D ▾

PARTNERING

INVESTOR RELATIONS ▾


BLOG

CONTACT





**Hemispherx is engaged
in the clinical
development of new
drug entities for the
treatment of seriously
debilitating disorders**



**Investor
Relations**



Products



R & D

Hemispherx is committed to providing up to date information to shareholders, analysts, and potential investors. Get the latest from our blog.

[Learn More](#)

Hemispherx's flagship products include Ampligen® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.

[Learn More](#)

Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.

[Learn More](#)

Hemispherx is engaged in the clinical development of new